Navigation Links
InQ Biosciences Introduces First Fully Integrated Cell Research System
Date:7/13/2010

HUNTSVILLE, Ala., July 13 /PRNewswire/ -- InQ Biosciences, a provider of innovative technologies for cell growth and research, announced its plans to launch the InQ™ Cell Research System during the fourth quarter of 2010. InQ is the first fully integrated system that creates a high fidelity in vivo environment for studying stem cells, plus nerve, brain, and other mammalian cells for disease research.

"The InQ system is the only cell research instrument that combines a dynamic software-controlled sample environment with powerful imaging and real-time data collection," said Aaron Hammons, President and Chief Technology Officer, InQ Biosciences. "Our system's exclusive capability to tightly control environmental parameters with correlated sample feedback will create a new paradigm in cell biology research. Scientists will be empowered with novel and more relevant approaches to discovery as they pursue the causes of cancer and neurodegenerative and cardiovascular diseases," Hammons said.

The benchtop system automates the cell culture process by enclosing the cells in a sealed, sterile removable cartridge that slides into the instrument. An onboard computer precisely controls the mix and flow of nutritive media and gasses and regulates the temperature. "Users will reap the benefits of extended cell growth and unprecedented experiment reproducibility and standardization. Now researchers can easily simulate hundreds of disease states, including stroke, heart attack, Alzheimer's, and ALS," said Hammons.

A built-in high-resolution microscope and camera record the assay at scheduled intervals, and can send the images to the researcher anywhere in the world via the Internet and smart phone. Adjustments to the experiment can be made remotely, as well.

The InQ System fits easily into research workflows and integrates with most laboratory information management systems. It requires fewer samples to attain study goals, generates more data points for greater accuracy of results, and dramatically reduces the number of failed experiments," Hammons said.

Units will be shipped to early access partners beginning in September, with commercial launch scheduled in the fourth quarter. For more information on the InQ System, contact info@inqbio.com or 866-735-9684, or visit http://www.inqbio.com. Follow InQ Biosciences on Twitter at http://twitter.com/InQbio.

About InQ Biosciences

InQ Biosciences is a provider of innovative technologies for cell growth and research. The company's InQ Cell Research System will empower scientists to unlock novel and more powerful approaches to cell-based discovery. The firm was founded in 2007 with technology originating from the University of Alabama in Huntsville. Series B financing was completed in May 2010 and commercial launch of its InQ system is scheduled for the fourth quarter of 2010. For more information, visit http://www.inqbio.com. Follow InQ Biosciences on Twitter at http://twitter.com/InQbio.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Aaron Hammons: https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=96140


'/>"/>
SOURCE InQ Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Energy Biosciences Institue named "Deal of Distinction" by tech-transfer group
2. Motorola Introduces Mobile Biometric Identification for Handheld Computers
3. Advanced Analogic Technologies Introduces Lowest-Power Load Switch Available for Biometric Security Devices
4. Olympus introduces the VisiGlide, a single-use guidewire
5. Cermetek Introduces Medically Approved Modem Module
6. Orbel Introduces the Board Shielding Wizard
7. New way to make malaria medicine also first step in finding new antibiotics
8. Complete Genomics launches, becomes worlds first large-scale human genome sequencing company
9. Digital zebrafish embryo provides the first complete developmental blueprint of a vertebrate
10. Synaptics to Report First Quarter Results on October 23
11. Alzheimers disease research attracts first partner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2017)... 4, 2017  CES 2017 – Valencell , ... today announced the launch of two new versions ... highly-accurate biometric sensor modules that incorporate the best ... and expertise. The two new designs include Benchmark ... hearables, and Benchmark BW2.0, a 2-LED version of ...
(Date:12/22/2016)...  As part of its longstanding mission to improve genetic ... recently released its latest children,s book, titled The ... the topics of inheritance and variation of traits that are ... elementary school classrooms in the US. The ... Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/20/2016)... The rising popularity of mobility services ... stoking significant interest in keyless access systems. Following ... energy (BLE), biometrics and near-field communication (NFC) are ... wireless technologies in the automotive industry. This evolution ... systems opens the market to specialist companies such ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... http://www.Financialbuzz.com - According ... causes of death worldwide. There were 8.2 million cancer ... related deaths increased gradually over time, the death rates ... various cancers continues to drive demand of biological therapies ... Market Insights, Inc. cancer biological therapy market size was USD ...
(Date:1/19/2017)... Jan. 19, 2017  Market Research Future has a half cooked ... Liquid Biopsy is growing rapidly and expected to reach USD 450 ... Highlights ... Liquid Biopsy Market has been assessed as a swiftly growing market ... boom in the coming future. There has been a tremendous growth ...
(Date:1/19/2017)... , Jan 19, 2017 Research and Markets ... has announced the addition of ... Material, Application - Forecast to 2025" report to their ... The report provides a detailed analysis on current and ... forecasts till 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 ... Inc., a privately-held immunotherapeutics company targeting infectious diseases, ... for the merger of PharmAthene and Altimmune in ... Venture Fund, HealthCap, Truffle Capital and Redmont Capital. ... diversified immunotherapeutics company with four clinical stage and ...
Breaking Biology Technology: